Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3200001 | 0.90 | PTGER1 (0.59) | PTGER1PTGER3 | |
| SCHEMBL3218324 | 0.88 | PTGER1 (0.80) | PTGER1PTGER3 | |
| SCHEMBL3221200 | 0.85 | PTGER1 (1.00) | PTGER1PTGER3 | |
| SCHEMBL3207444 | 0.84 | PTGER1 (0.79) | PTGER1PTGER3 | |
| SCHEMBL3221027 | 0.83 | PTGER1 (0.74) | PTGER1PTGER3 | |
| SCHEMBL3214872 | 0.81 | PTGER1 (0.89) | PTGER1PTGER3 | |
| SCHEMBL3217737 | 0.81 | PTGER1 (0.78) | PTGER1PTGER3 | |
| SCHEMBL3203352 | 0.81 | PTGER1 (0.72) | PTGER1PTGER3 | |
| SCHEMBL3221088 | 0.80 | PTGER1 (0.70) | PTGER1PTGER3 | |
| SCHEMBL3213004 | 0.80 | PTGER1 (0.70) | PTGER1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | claimed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED | 2010-03-04 | — | — | US | disclosed |
| WO-2008098978-A2 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056527-A1 | BENZOFURAN COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE ACTION OF PGE2 AT THE EP1 RECEPTOR | PTGER1, PTGER2, PTGER4 | PTGER1 1/4885PTGER3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.